Lactobacillus rhamnosus LRa05 and Reduced Pepsinogen I Level

Doses used in studies

CFU/day: 10 billion (median 10 billion, IQR 10 billion–10 billion) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Although LRa05 did not significantly improve the success rate of H. pylori eradication therapy, it has the potential to improve liver function and reduced levels of inflammatory markers such as IL-6 and TNF-α in the body, regulating the inflammatory response. In addition, it played a positive role in alleviating the adverse symptoms and gut microbiota disturbances caused by eradication therapy, providing a possible way to improve the overall health of patients and demonstrating promising clinical potential.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
abdominal painReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
acid refluxReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
bloatingReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
diarrheaReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication

1 of 1 paper

Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.
- 2024-08-21
- RCT
- Frontiers in immunology 15
- - Yue Niu
  - Jing Li
  - Hongwei Qian
  - Chunli Liang
  - Xinyi Shi
  - Shurui Bu
- PubMed: 39234246
- DOI: 10.3389/fimmu.2024.1450414
12 Insights on
- Reduced Pepsinogen I Level
- High evidence
- Clinical
Significant reductions in neutrophil count, alanine aminotransferase, aspartate aminotransferase, pepsinogen I, interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) (p < 0.05) suggest that LRa05 supplementation may mitigate inflammation, enhance liver function, and potential aid in early cancer prevention.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
1 × 10^10 CFU/day for 4 weeks

Lactobacillus rhamnosus LRa05 and Reduced Pepsinogen I Level

Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.